Becton, Dickinson and Company(BD), a leading global medical technology company, has come out with its rapid, point-of-care, SARS-CoV-2 antigen test. Easy-to-use, the portable instrument delivers real-time results in 15 minutes, enabling faster decision-making while the patient is still
in the premises. The company expects commercial availability of this new assay at the end of October for countries in Europe that recognize the CE mark.
The COVID-19 test has been available in the United States since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
The BD Veritor™ Plus System can test for both COVID-19 and influenza A+B in parallel during flu season, on the same platform.
Interested in Intellizence Demo?
Intellizence is an award-winning AI-powered business signal intelligence platform, that helps you to discover sales and risk signals in target companies as well as stay informed about emerging industry trends and regulatory changes.
Identify Emerging Opportunities & Risks